|Primary Industry:||Health & Medical Devices|
|Executive Summary:||FluimediX will provide a microfluidic platform – The NanoCycler™ - enabling the identification of SNPs in a portable environment, based on polymer disposables.
The emerging market of pharmacogenetics relates to the understanding of genetically determined drug-response. Recent advances within genetic research have paved the way to an understanding of the influence of specific genetic variations on drug metabolism.
We will target FDA validated biomarkers in the Cytocrome P450 enzyme group, thus taking a regulatory short cut to market.
Initially we will address the administration of psychiatric drugs for the following reasons:
· Lack of efficacy leads to a “trial and error” process that takes months to conclude.
· Side effects arising from erroneous dose are the number one reason for patients terminating treatment.
Elements of our technology utilises soon-to-expire 3’rd party IPR. This aspect creates a perfect “window of opportunity” in relation to our development period. Additionally - by the very nature of our technologies - we are able to “circumvent” 3’rd party IPR (e.g. Multiplex and Hot-Start PCR)|